AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2689986 — intervention group
Group type: EXPERIMENTAL
Intervention: F 1.8 formula (1.8 g protein/100 mL)
Number of subjects: 30
Study 2689986 — intervention group
Group type: COMPARATOR
Intervention: F 1.3 formula (1.3 g protein/100 mL)
Number of subjects: 30
Study 2689986 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed (BF)
Number of subjects: 30
Study 30535101 — intervention group
Group type: EXPERIMENTAL
Intervention: SparkPeople plus activity tracker, Fitbit Charge (n = 18)
Number of subjects: 35
Study 30535101 — intervention group
Group type: COMPARATOR
Intervention: Fitbit only (wait-list active control group, n = 17)
Number of subjects: 35
Study 30241706 — intervention group
Group type: EXPERIMENTAL
Intervention: HHHF intervention (16-week home environment-focused coaching)
Number of subjects: 349
Study 30241706 — intervention group
Group type: EXPERIMENTAL
Intervention: HHHF intervention
Number of subjects: 349
Study 30241706 — intervention group
Group type: COMPARATOR
Intervention: Control (health education materials by mail)
Number of subjects: 349
Study 28005623 — intervention group
Group type: EXPERIMENTAL
Intervention: HAED
Number of subjects: 0
Study 28005623 — intervention group
Group type: COMPARATOR
Intervention: HAPER
Number of subjects: 0
Study 26025767 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 1240
Study 26025767 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1240
Study 23197590 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fortification (MF)
Number of subjects: 84
Study 23197590 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fortification (AF)
Number of subjects: 84
Study 23197590 — intervention group
Group type: COMPARATOR
Intervention: Standard fortification (SF)
Number of subjects: 84
Study 22333250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR)
Number of subjects: 74
Study 22333250 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNI)
Number of subjects: 74
Study 19358498 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment at Tinghui (GB 2), Yifeng (TE 17), Hegu (LI 4), Xiaxi (GB 43), Zhongzhu (TE 3)
Number of subjects: 60
Study 19358498 — intervention group
Group type: COMPARATOR
Intervention: Medication group with intravenous 6% low molecule dextran 500 mL with ATP and coenzyme A, and oral Nimodipine, Gold Theragan
Number of subjects: 60
Study 16935718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT scans at 15 mA
Number of subjects: 5
Study 16935718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT scans (tube current < 15 mA) with edge-preserving smoothing filter
Number of subjects: 5
Study 16935718 — intervention group
Group type: COMPARATOR
Intervention: High-dose CT scans (55 mA)
Number of subjects: 5
Study 16935718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT scans
Number of subjects: 5
Study 15568948 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence microscopy (OCM)
Number of subjects: 13
Study 15568948 — intervention group
Group type: COMPARATOR
Intervention: Confocal microscopy
Number of subjects: 13
Study 11766661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine instillation
Number of subjects: 118
Study 11766661 — intervention group
Group type: COMPARATOR
Intervention: Control (no ropivacaine instillation)
Number of subjects: 118
Study 9764629 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HRT
Number of subjects: 63
Study 9764629 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 63
Study 8310977 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (mean daily dose 8.8 mg)
Number of subjects: 125
Study 8310977 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (mean daily dose 83.7 mg)
Number of subjects: 125
Study 8310977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 2897780 — intervention group
Group type: EXPERIMENTAL
Intervention: bevantolol (200 to 400 mg)
Number of subjects: 39
Study 2897780 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (50 to 100 mg)
Number of subjects: 39
Study 29433430 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to second-line ART immediately
Number of subjects: 80
Study 29433430 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (not switched) according to WHO guidelines
Number of subjects: 80
Study 28110896 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab 75 mg IV
Number of subjects: 50
Study 28110896 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg SC
Number of subjects: 50
Study 28110896 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab 75 mg IV and SC
Number of subjects: 50
Study 26144571 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 18
Study 26144571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24094008 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual arch for space maintenance (n = 30)
Number of subjects: 44
Study 24094008 — intervention group
Group type: COMPARATOR
Intervention: Control group with no orthodontic treatment (n = 14)
Number of subjects: 44
Study 24094008 — intervention group
Group type: COMPARATOR
Intervention: Comparison between EG and CG
Number of subjects: 44
Study 21507573 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation
Number of subjects: 214
Study 21507573 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 214
Study 21507573 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy
Number of subjects: 214
Study 21507573 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment-as-usual)
Number of subjects: 214
Study 18499007 — intervention group
Group type: EXPERIMENTAL
Intervention: AquaLase liquefaction cataract surgery
Number of subjects: 63
Study 18499007 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) phacoemulsification cataract surgery
Number of subjects: 63
Study 18499007 — intervention group
Group type: EXPERIMENTAL
Intervention: AquaLase liquefaction cataract surgery (subgroup analysis of diabetic patients)
Number of subjects: 63
Study 18499007 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) phacoemulsification cataract surgery (subgroup analysis of diabetic patients)
Number of subjects: 63
Study 16510488 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA/THC users
Number of subjects: 41
Study 16510488 — intervention group
Group type: EXPERIMENTAL
Intervention: THC users
Number of subjects: 41
Study 16510488 — intervention group
Group type: COMPARATOR
Intervention: Non-drug users
Number of subjects: 41
Study 12395616 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve compression test (MNCT)
Number of subjects: 18
Study 12395616 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MNCT)
Number of subjects: 18
Study 10446869 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice daily)
Number of subjects: 46
Study 10446869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 10446869 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 46
Study 7576676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 39
Study 7576676 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 39
Study 2107060 — intervention group
Group type: EXPERIMENTAL
Intervention: Niflumic acid (4 capsules of 250 mg daily)
Number of subjects: 231
Study 2107060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 35189 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0
Study 35189 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 35189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6626105 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-assisted exposure
Number of subjects: 12
Study 6626105 — intervention group
Group type: COMPARATOR
Intervention: Self-controlled exposure
Number of subjects: 12
Study 6626105 — intervention group
Group type: COMPARATOR
Intervention: Self-controlled exposure (Post-treatment)
Number of subjects: 12
Study 6626105 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (6-month follow-up)
Number of subjects: 12
Study 31501084 — intervention group
Group type: EXPERIMENTAL
Intervention: early salvage radiotherapy (eSRT) initiated at PSA <0.5 ng/ml
Number of subjects: 1458
Study 31501084 — intervention group
Group type: COMPARATOR
Intervention: late salvage radiotherapy (lSRT) initiated at PSA ≥0.5 ng/ml
Number of subjects: 1458
Study 30345498 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic Obturator Nerve Block (ONB)
Number of subjects: 66
Study 30345498 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal Obturator Nerve Block (ONB)
Number of subjects: 66
Study 29847486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (target SBP < 120 mmHg)
Number of subjects: 132
Study 29847486 — intervention group
Group type: COMPARATOR
Intervention: Modest blood pressure control (target SBP < 140 mmHg)
Number of subjects: 132
Study 29847486 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 132
Study 26515607 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting paliperidone palmitate
Number of subjects: 0
Study 26515607 — intervention group
Group type: COMPARATOR
Intervention: Long-acting haloperidol decanoate
Number of subjects: 0
Study 25286782 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MS)
Number of subjects: 92
Study 25286782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 22229677 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO intervention
Number of subjects: 10
Study 20102927 — intervention group
Group type: EXPERIMENTAL
Intervention: RV TDI systolic velocity
Number of subjects: 102
Study 20102927 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy
Number of subjects: 102
Study 20102927 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin treatment
Number of subjects: 102
Study 20102927 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 102
Study 20102927 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmitral Doppler to mitral annular TDI early diastolic velocity ratio
Number of subjects: 102
Study 20102927 — intervention group
Group type: EXPERIMENTAL
Intervention: RV TDI early diastolic velocity
Number of subjects: 102
Study 20102927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of early to late RV diastolic TDI velocities
Number of subjects: 102
Study 20102927 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased RV systolic velocity
Number of subjects: 102
Study 20102927 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased ratio of early to late RV diastolic TDI velocities
Number of subjects: 102
Study 20102927 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BNP
Number of subjects: 102
Study 17592238 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat fitting group (R1 > R2)
Number of subjects: 47
Study 17592238 — intervention group
Group type: COMPARATOR
Intervention: Steep fitting group (R1 < R2)
Number of subjects: 47
Study 16247225 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler ultrasound-guided target biopsy
Number of subjects: 302
Study 16247225 — intervention group
Group type: COMPARATOR
Intervention: Sextant biopsy
Number of subjects: 302
Study 16247225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PDU and sextant biopsy
Number of subjects: 302
Study 16247225 — intervention group
Group type: EXPERIMENTAL
Intervention: Target biopsy
Number of subjects: 302
Study 12385435 — intervention group
Group type: EXPERIMENTAL
Intervention: B-LAC (bismuth, clarithromycin, amoxicillin, and lansoprazole)
Number of subjects: 56
Study 12385435 — intervention group
Group type: COMPARATOR
Intervention: B-LAA (bismuth, azithromycin, amoxicillin, and lansoprazole)
Number of subjects: 56
Study 10442379 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine plus UFT therapy
Number of subjects: 136
Study 10442379 — intervention group
Group type: COMPARATOR
Intervention: Endocrine-only therapy
Number of subjects: 136
Study 7605858 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg/day for 10 weeks, tapered to 6 mg/day after 8 weeks)
Number of subjects: 18
Study 7605858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg/day for 10 weeks, tapered to 5 mg/day after 2 weeks)
Number of subjects: 18
Study 7605858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Budesonide and Prednisolone)
Number of subjects: 18
Study 2192700 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol-240
Number of subjects: 0
Study 2192700 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol-320
Number of subjects: 0
Study 498413 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (1.0‐1.5 mg/kg) as the free drug (for 45 min or 4 h)
Number of subjects: 15
Study 498413 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin bound to a DNA carrier (for 5‐6 h)
Number of subjects: 15
Study 31227307 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cytoreductive nephrectomy (CN) followed by sunitinib
Number of subjects: 0
Study 31227307 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib followed by deferred CN 24h after the last dose of sunitinib
Number of subjects: 0
Study 28202686 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin pre-treatment
Number of subjects: 72
Study 28202686 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin post-treatment
Number of subjects: 72
Study 28202686 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle alone)
Number of subjects: 72
Study 28202686 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin pre-treatment and post-treatment
Number of subjects: 72
Study 25851020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine infusion via saphenous catheter
Number of subjects: 50
Study 25851020 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline infusion via saphenous catheter
Number of subjects: 50
Study 24070181 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured diabetes and hypertension clinical record (SR) introduced in intervention clinics after training doctors.
Number of subjects: 60
Study 24070181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SR implementation).
Number of subjects: 60
Study 20842754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger root powder capsules
Number of subjects: 60
Study 20842754 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study 19235038 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 0
Study 19235038 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25-OH-VitD)
Number of subjects: 0
Study 19235038 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH)
Number of subjects: 0
Study 17490569 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluvit treatment
Number of subjects: 87
Study 17490569 — intervention group
Group type: COMPARATOR
Intervention: Control (500 ml normal saline infusion)
Number of subjects: 87
Study 15472178 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.074 mg/kg, administered subcutaneously three times per week until height velocity decreased to less than 1.5 cm/year
Number of subjects: 68
Study 15472178 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered subcutaneously three times per week until height velocity decreased to less than 1.5 cm/year
Number of subjects: 68
Study 12042081 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led HIV prevention programme
Number of subjects: 0
Study 12042081 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education programme
Number of subjects: 0
Study 9854471 — intervention group
Group type: EXPERIMENTAL
Intervention: Image Cytometry DNA analysis
Number of subjects: 21
Study 9854471 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 and p21/WAF1 evaluation
Number of subjects: 21
Study 7828383 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment for 4 weeks
Number of subjects: 0
Study 7828383 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2132641 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin (250 ml 20%)
Number of subjects: 18
Study 2132641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 527635 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 20 mg
Number of subjects: 18
Study 527635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Number of subjects: 18
Study 527635 — intervention group
Group type: EXPERIMENTAL
Intervention: Noscapine 30 mg
Number of subjects: 18
Study 527635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30873102 — intervention group
Group type: EXPERIMENTAL
Intervention: rMV (vibration group–VG)
Number of subjects: 22
Study 30873102 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group–CG)
Number of subjects: 22
Study 29996204 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r plus DSV for 12 weeks (Group A)
Number of subjects: 410
Study 29996204 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks (Group B)
Number of subjects: 410
Study 29996204 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r plus DSV after placebo in open-label phase (Group B)
Number of subjects: 410
Study 27846927 — intervention group
Group type: COMPARATOR
Intervention: Standard health check invitation only
Number of subjects: 12459
Study 27846927 — intervention group
Group type: EXPERIMENTAL
Intervention: QBE questionnaire followed by a standard invitation
Number of subjects: 12459
Study 27846927 — intervention group
Group type: EXPERIMENTAL
Intervention: QBE questionnaire with offer of a financial incentive to return the questionnaire, followed by a standard invitation
Number of subjects: 12459
Study 27846927 — intervention group
Group type: COMPARATOR
Intervention: Opportunistic health checks
Number of subjects: 12459
Study 25156453 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT)
Number of subjects: 17
Study 22086510 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-axis needle guide (NG)
Number of subjects: 33
Study 22086510 — intervention group
Group type: COMPARATOR
Intervention: Long-axis free hand (L-FH)
Number of subjects: 33
Study 22086510 — intervention group
Group type: COMPARATOR
Intervention: Short-axis free hand (S-FH)
Number of subjects: 33
Study 20638463 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetyl-cysteine (NAC) 1200 mg/day for 14 days
Number of subjects: 53
Study 20638463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 17938371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine XR
Number of subjects: 239
Study 15269313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus irinotecan
Number of subjects: 329
Study 15269313 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab monotherapy
Number of subjects: 329
Study 11673326 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing with the right hand
Number of subjects: 0
Study 11673326 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing with the left hand
Number of subjects: 0
Study 11673326 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 0
Study 9751064 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (1000 microg/day)
Number of subjects: 10
Study 7870548 — intervention group
Group type: EXPERIMENTAL
Intervention: Throwing paddleball in noise conditions
Number of subjects: 56
Study 7870548 — intervention group
Group type: COMPARATOR
Intervention: Throwing paddleball in quiet conditions
Number of subjects: 56
Study 3416617 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses under low luminance and contrast conditions
Number of subjects: 4
Study 3416617 — intervention group
Group type: COMPARATOR
Intervention: Spectacles under low luminance and contrast conditions
Number of subjects: 4
Study 29520944 — intervention group
Group type: EXPERIMENTAL
Intervention: Teethmate AP (TAP) desensitizer paste
Number of subjects: 50
Study 29520944 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 50
Study 29520944 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TAP and PLA
Number of subjects: 50
Study 28479257 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) with a bridge of 30 mL of 0.5% bupivacaine
Number of subjects: 83
Study 28479257 — intervention group
Group type: COMPARATOR
Intervention: Indwelling interscalene nerve block (IINB)
Number of subjects: 83
Study 24535359 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine (0.1 mg/kg)
Number of subjects: 90
Study 24535359 — intervention group
Group type: EXPERIMENTAL
Intervention: flurbiprofen axetil (1 mg/kg)
Number of subjects: 90
Study 24535359 — intervention group
Group type: COMPARATOR
Intervention: control group (physiological saline)
Number of subjects: 90
Study 23063354 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT (infusional 5‐FU, leucovorin, oxaliplatin, and docetaxel 50 mg/m(2))
Number of subjects: 143
Study 23063354 — intervention group
Group type: COMPARATOR
Intervention: FLO (infusional 5‐FU, leucovorin, and oxaliplatin)
Number of subjects: 143
Study 23063354 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT
Number of subjects: 143
Study 23063354 — intervention group
Group type: COMPARATOR
Intervention: FLO
Number of subjects: 143
Study 20739846 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant interferon (IFN) therapy
Number of subjects: 1769
Study 20739846 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1769
Study 18379536 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-containing peritoneal dialysis solution
Number of subjects: 13
Study 16391217 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (3 g 3 times a day for 6 months)
Number of subjects: 153
Study 16391217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 12604748 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's Association care consultation service
Number of subjects: 157